Orchestra BioMed Holdings (OBIO) Other Non Operating Income (2022 - 2026)
Orchestra BioMed Holdings (OBIO) posted quarterly Other Non Operating Income of -$35000.0 for Q1 2026, down 218.18% quarter-over-quarter from -$11000.0 in Q1 2024.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Other Non Operating Income (2022 - 2026) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Other Non Operating Income for 3 consecutive years, with -$35000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income changed N/A year-over-year to -$35000.0; the TTM figure through Mar 2026 stood at -$35000.0 (changed N/A YoY), while the FY2025 annual figure was $254000.0, up 2409.09% from the prior year.
- Other Non Operating Income fell to -$35000.0 in Q1 2026 per OBIO's latest filing, from -$11000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $682000.0 in Q2 2022 and bottomed at -$35000.0 in Q1 2026.
- Historically, Other Non Operating Income has averaged $212000.0 across 3 years, with a median of -$11000.0 in 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 324.80 Mn | 130.27 Mn | 63,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 324,000.00 |
| Mar 31, 2026 | -35,000.00 |
| Mar 31, 2024 | -11,000.00 |
| Jun 30, 2022 | 682,000.00 |